Maria Buti

Summary

Affiliation: Hospital Vall d'Hebron
Country: Spain

Publications

  1. ncbi request reprint Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    J Hepatol 33:651-8. 2000
  2. ncbi request reprint Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B
    M Buti
    Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle Hebron s n, Barcelona 08035, Spain
    J Infect Dis 183:1277-80. 2001
  3. ncbi request reprint Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Hepatology 35:930-6. 2002
  4. ncbi request reprint [Study of hepatitis B virus replication and infection by other hepatitis viruses in patients with chronic hepatitis B virus infection]
    M Buti
    Servicio de Hepatología Laboratorio de Bioquímica Hospital Universitario Vall d Hebron Barcelona Spain
    Gastroenterol Hepatol 25:295-8. 2002
  5. ncbi request reprint A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 17:687-94. 2003
  6. ncbi request reprint Adefovir dipivoxil
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Drugs Today (Barc) 39:127-35. 2003
  7. ncbi request reprint A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation
    Maria Buti
    Servicio de Hepatologi a, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
    J Hepatol 38:811-7. 2003
  8. ncbi request reprint Entecavir, FTC, L-FMAU, LdT and others
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Paseo Valle de Hebron 119, Barcelona 08035, Spain
    J Hepatol 39:S139-42. 2003
  9. doi request reprint Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D
    Melanie Schaper
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona 08035, Spain
    J Hepatol 52:658-64. 2010
  10. ncbi request reprint Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
    Isabel Campos-Varela
    Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Ann Hepatol 10:180-7. 2011

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    J Hepatol 33:651-8. 2000
    ..The objective of this study was to determine if the incremental sustained response rate of combination therapy is sufficient to outweigh its extra cost...
  2. ncbi request reprint Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B
    M Buti
    Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle Hebron s n, Barcelona 08035, Spain
    J Infect Dis 183:1277-80. 2001
    ..Therefore, quantitative HBV DNA testing is very useful in deciding whether to continue therapy, because of the low likelihood of response in patients who remain HBV DNA positive at month 3 of treatment...
  3. ncbi request reprint Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Hepatology 35:930-6. 2002
    ..Higher doses of peginterferon alfa-2b also accelerate viral clearance...
  4. ncbi request reprint [Study of hepatitis B virus replication and infection by other hepatitis viruses in patients with chronic hepatitis B virus infection]
    M Buti
    Servicio de Hepatología Laboratorio de Bioquímica Hospital Universitario Vall d Hebron Barcelona Spain
    Gastroenterol Hepatol 25:295-8. 2002
    ..To study hepatitis B virus (HBV) replication in a series of patients with HBV infection and to analyze the frequency of associated hepatitis C virus (HCV) and hepatitis D (HDV) infection...
  5. ncbi request reprint A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 17:687-94. 2003
    ..To estimate the cost-effectiveness of therapy and analyse the effect of therapy compliance in naive patients with chronic hepatitis C...
  6. ncbi request reprint Adefovir dipivoxil
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Drugs Today (Barc) 39:127-35. 2003
    ..Adefovir is an important new addition to current first-line treatments for HBeAg and anti-HBe-positive chronic hepatitis B, as well as being rescue therapy for lamivudine-resistant HBV strains...
  7. ncbi request reprint A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation
    Maria Buti
    Servicio de Hepatologi a, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
    J Hepatol 38:811-7. 2003
    ..To compare the efficacy in preventing hepatitis B virus (HBV) recurrence of lamivudine vs. lamivudine plus hepatitis B immune globulin (HBIg) after a short course of HBIg and lamivudine in liver transplanted chronic hepatitis B patients...
  8. ncbi request reprint Entecavir, FTC, L-FMAU, LdT and others
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Paseo Valle de Hebron 119, Barcelona 08035, Spain
    J Hepatol 39:S139-42. 2003
    ..Currently, the drugs most likely to fulfill these criteria are the nucleoside analogs...
  9. doi request reprint Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D
    Melanie Schaper
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona 08035, Spain
    J Hepatol 52:658-64. 2010
    ..This study presents a real-time reverse-transcription PCR (rt-RT-PCR) assay for hepatitis delta virus (HDV) RNA quantification, designed to clarify the interplay between HDV and hepatitis B virus (HBV) in chronic infection...
  10. ncbi request reprint Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
    Isabel Campos-Varela
    Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Ann Hepatol 10:180-7. 2011
    ..The risk of recurrent hepatitis B virus (HBV) infection and prognosis of liver transplantation in patients with HBV has dramatically changed with the use of prophylaxis including hepatitis B immune globulin (HBIg) and antiviral agents...
  11. ncbi request reprint Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin
    Maria Buti
    Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain
    J Hepatol 40:527-32. 2004
    ..We examined the usefulness of measuring total HCV Core Ag in early treatment with peginterferon alpha-2b and ribavirin in genotype 1 patients in the prediction of response and compared the results with those from HCV RNA quantification...
  12. ncbi request reprint Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response
    Francisco Rodriguez-Frias
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Antivir Ther 13:991-9. 2008
    ..Virological characteristics useful for predicting response have not been clearly elucidated. We determined pretreatment virological markers to predict non-response and possible emergence of new variants during therapy...
  13. ncbi request reprint Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence
    Maria Buti
    Hospital General Valle de Hebrón and CIBER EHD, Barcelona, Spain
    Transplantation 84:650-4. 2007
    ..Patients who adhere to long-term prophylaxis with lamivudine after early withdrawal of HBIg have a low risk of HBV recurrence, similar to those who receive combination prophylaxis...
  14. ncbi request reprint Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy
    Rosendo Jardi
    Department of Biochemistry, Hospital General Universitario Vall d Hebron, Paseo Valle Hebron s n, Servicio de Bioquimica, Barcelona 08035, Spain
    J Hepatol 49:695-701. 2008
    ..The frequency of mixed hepatitis B virus (HBV) genotypes in chronic HBV (CHB) and genotype changes during natural disease evolution and as a result of antiviral therapy were investigated...
  15. ncbi request reprint Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues
    Francisco Rodriguez-Frias
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Med Virol 79:1671-3. 2007
    ..Despite the presence of these variants, the patient has had a complete virological response...
  16. doi request reprint Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
    Maria Buti
    Servicio de Hepatologi a, Hospital Vall d Hebrón and Ciber ehd del Instituto Carlos III, Barcelona, Spain
    J Hepatol 51:640-6. 2009
    ..The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB...
  17. ncbi request reprint Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA
    Rosendo Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Hepatology 40:133-9. 2004
    ..In conclusion, the DBS sample is useful for HBV DNA quantification, genotyping, and detection of precore mutant and YMDD variants. All four determinations can be completed with a single drop of dried blood...
  18. ncbi request reprint Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers
    Rosendo Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Hepatol 40:507-14. 2004
    ..To determine the prevalence and significance of hepatitis B virus (HBV) basic core promoter (BCP) mutations and to establish their relationship with precore (preC) mutations, HBV genotypes and HBV-DNA levels...
  19. doi request reprint Current trends in chronic hepatitis B management: results of a questionnaire
    Iñigo Les
    Liver Unit, Hospital General Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
    Eur J Gastroenterol Hepatol 21:1177-83. 2009
    ..Aim of this study was to analyze general knowledge, therapeutic and diagnostic trends of physicians treating CHB in Spain...
  20. doi request reprint Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
    Maria Buti
    Liver Unit, Valle d Hebron Ciberehd University Hospital, and Biomedical Research Center Network in the Area of Hepatic and Digestive Disorders of the Carlos III Health Institute, Barcelona, Spain
    Hepatology 52:1201-7. 2010
    ..5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a <2-log drop in HCV RNA at week 8, SVR was 39% in the 72-week arm and 19% in the 48-week arm...
  21. ncbi request reprint Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1
    Maria Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Pharmacoeconomics 23:1043-55. 2005
    ..The monitoring of early virological response (EVR) is therefore an important tool for quickly identifying non-responders, permitting therapy discontinuation and avoiding adverse effects and costs...
  22. ncbi request reprint Drugs in development for hepatitis B
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Drugs 65:1451-60. 2005
    ....
  23. doi request reprint [Quantification of hepatitis B virus HBsAg: clinical implications]
    Maria Buti
    Servicio de Hepatologia, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 138:483-8. 2012
    ..The role of the quantification of HBsAg in the treatment with nucleoside analogues is still not well understood and requires further studies...
  24. ncbi request reprint Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes
    Maria Buti
    Liner Unit, Hospital General Universitari Pall d Hebron, Barcelona, Spain
    J Clin Virol 34:S79-82. 2005
    ..Analyses of both naturally occurring viral variants and in vitro mutagenesis studies have identified some mutations that have a role in viral latency, pathogenesis of liver disease, immune escape, and resistance to antiviral therapy...
  25. pmc Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy
    Rosendo Jardi
    Departments of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Clin Microbiol 47:485-8. 2009
    ..The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences...
  26. doi request reprint A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model
    Clara Ramírez
    Biochemistry Department, Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Antiviral Res 98:273-83. 2013
    ..Nonetheless, specific mutations, such as insertions and deletions, were only detected by cloning. A filter should be designed to analyze cloning sequences, and UDPS filters should be improved to include the specific mutations...
  27. pmc Prevalence of hepatitis E virus infection in children in the northeast of Spain
    Maria Buti
    Liver Unit, Biochemistry Departament, Hospital Universitario Valle Hebron and CIBER EHD of Instituto Carlos III, Passeig Vall d Hebron 119 121, 08035 Barcelona, Spain
    Clin Vaccine Immunol 15:732-4. 2008
    ..IgG anti-HEV antibodies were detected in 57 (4.6%) of the 1,249 samples analyzed, suggesting that some children are exposed to HEV in early childhood...
  28. doi request reprint Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab
    Mayra J Sanchez
    Hospital Vall d Hebron, Liver Unit, CIBERehd Institute Carlos III, Paseo de Vall d Hebron, 08035 Barcelona, Spain
    J Hepatol 51:1091-6. 2009
    ..Patients with severe reactivation often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with severe HBV reactivation...
  29. ncbi request reprint De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection
    Jose L Tovar
    Servicio de Nefrologia, Hospital General Universitario Valle de Hebron, Barcelona 08035, Spain
    Int Urol Nephrol 40:539-41. 2008
    ..The patient exhibited a total remission when the antiviral treatment was discontinued...
  30. ncbi request reprint Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
    Maria Buti
    Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain Electronic address
    Gastroenterology 146:744-753.e3. 2014
    ..We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis...
  31. doi request reprint Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients
    Maria Buti
    CIBER on Liver and Digestive Diseases, Hospital Vall d Hebron, corrected Barcelona, Spain
    Eur J Gastroenterol Hepatol 24:535-42. 2012
    ..Entecavir is an effective treatment for chronic hepatitis B. However, data from clinical practice are limited, especially in hepatitis B e antigen (HBeAg)-positive patients...
  32. pmc Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome
    Maria Homs
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto Carlos III Corsega 180, 08036, Barcelona, Spain
    Nucleic Acids Res 39:8457-71. 2011
    ..Analysis of ε-signal variability suggested the essential nature of the ε structural motif and that certain nucleotides may be involved in ε signal functions...
  33. ncbi request reprint Sporadic cases of acute autochthonous hepatitis E in Spain
    Maria Buti
    Liver Unit, Hospital General Universitario Valle Hebron, Paseo Valle de Hebron 119, 08035 Barcelona, Spain
    J Hepatol 41:126-31. 2004
    ..In industrialized countries hepatitis E virus (HEV) infection is rare and its diagnosis is difficult because the utility of available tests is not well established...
  34. ncbi request reprint Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference
    Maria Buti
    Hospital Vall d Hebron CIBER EHD, Liver Unit, Paseo Valle de Hebron 119, Barcelona 0803, Spain
    IDrugs 11:239-41. 2008
  35. ncbi request reprint Cirrhosis, Liver Transplantation and HIV Infection Are Risk Factors Associated with Hepatitis E Virus Infection
    Mar Riveiro-Barciela
    Liver Unit, Internal Medicine Department, Hospital Universitario Vall d Hebron, Barcelona, Spain
    PLoS ONE 9:e103028. 2014
    ..However, data regarding the epidemiology of hepatitis E in special populations is still limited...
  36. doi request reprint Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients
    Rafael Esteban
    Liver Unit, Hospital General, Universitario Valle Hebron and CIBERHED del Instituto Carlos III, Paseo Valle Hebron 119, Barcelona 08035, Spain
    Best Pract Res Clin Gastroenterol 26:445-53. 2012
    ..Besides, the physician's experience with each drug and the wishes of the patient also have to be considered...
  37. pmc Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome
    Francisco Rodriguez-Frias
    Biochemistry Department, Hospital Universitari Vall d Hebron, Vall d Hebron Institut de Recerca, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 7:e37874. 2012
    ....
  38. ncbi request reprint Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation
    Lluis Castells
    Liver Unit, Department of Biochemestry, Hospital General Vall d Hebron, Universitat Autonoma Barcelona, Barcelona, Spain
    Liver Transpl 8:892-900. 2002
    ....
  39. pmc Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain
    Maria Buti
    Liver Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Vaccine Immunol 13:1328-32. 2006
    ..68; 95% CI, 1.03 to 2.70). In conclusion, anti-HEV antibodies were detected in 7.3% of the Catalan population. The seroprevalence of anti-HEV antibodies increased with age and was associated with previous minor surgery...
  40. doi request reprint Analysis of the evolution in the circulation of HAV and HEV in eastern Spain by testing urban sewage samples
    Jesus Rodriguez-Manzano
    Department of Microbiology, Faculty of Biology, University of Barcelona, Avd Diagonal 645, 08028, Barcelona, Spain
    J Water Health 8:346-54. 2010
    ..However, these improvements would not have an equivalent effect on the circulation of HEV and this observation could be explained by the presence of animal reservoirs for HEV, which act as external sources of infections...
  41. ncbi request reprint Current therapies for chronic hepatitis B
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Ann Hepatol 2:108-12. 2003
  42. pmc Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis
    Wen Chun Liu
    Institute of Basic Medical Sciences, Department of Medicine, National Cheng Kung University, Tainan City 704, Taiwan, Republic of China, and Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Clin Microbiol 44:4491-7. 2006
    ..3% of 441 samples were accurately genotyped by the current assay. The method should be useful for genotyping and quantification of HBV DNA in areas where all genotypes exist...
  43. doi request reprint 1990-2010: two decades of interferon-based therapy
    Maria Buti
    Liver Unit, Hospital General, Universitario Valle Hebron, Paseo Valle Hebron 119, Barcelona 08035, Spain
    Clin Liver Dis 15:473-82. 2011
    ..Even with the development of new protease inhibitors, it is likely that interferon will remain an essential component of hepatitis C treatment...
  44. doi request reprint Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review
    Maria Buti
    Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
    Pharmacoeconomics 31:63-75. 2013
    ..Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications...
  45. ncbi request reprint Preparing the patient for success: treat or wait?
    Maria Buti
    Liver Unit, Hospital Universitario Vall d Hebron, Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Spain Electronic address
    Dig Liver Dis 45:S332-6. 2013
    ....
  46. ncbi request reprint Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
    Maria Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    J Hepatol 42:639-45. 2005
    ..Our aim was to estimate the future morbidity, mortality and costs of chronic HCV infection in a cohort of patients infected by HCV and to evaluate the impact of HCV therapy...
  47. ncbi request reprint Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients
    Maria Buti
    Liver Unit, Hospital General Universitario Valle de Hebron, Paseo Valle hebron 117, Barcelona 08035, Spain
    J Hepatol 44:S60-4. 2006
    ..Currently, the literature does not provide adequate information on the effect of HCV infection on the quality of life of HIV-HCV co-infected patients or the most cost-effective HCV therapy...
  48. pmc Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series
    Mònica Sabaté
    Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Universitari Vall d Hebron, Barcelona, Spain
    BMC Gastroenterol 11:80. 2011
    ..The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case...
  49. pmc New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
    Josep Quer
    Liver Unit, Internal Medicine Hospital Universitari Vall d Hebron, Institut de Recerca VHIR, Barcelona, Spain
    Infect Drug Resist 3:133-45. 2010
    ....
  50. ncbi request reprint Hepatitis E virus: new faces of an old infection
    Mar Riveiro-Barciela
    Liver Unit, Department of Internal Medicine, Vall d Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Ann Hepatol 12:861-70. 2013
    ..The best treatment option for HEV infection remains to be defined, but both ribavirin and peg-interferon may have a role in therapy for this condition. ..